March Poster Presentation at ACCIt's still a month away, but looks like Resverlogix will be presenting in a poster session focused on "Emerging Targets of Therapy for ACS." Norman Wong's name is underlined in the online schedule, suggesting that he will be the one presenting.
https://www.abstractsonline.com/pp8/#!/3658/presentation/35392
March 16, 2015, 9:45 - 10:30 AM in San Diego
1245-094 - RVX-208 the First Selective Bromodomain Extra-Terminal Protein Inhibitor Being Developed for Patients with High Residual Risks of Cardiovascular Disease
Authors: Norman Cw Wong, Jan Johansson, Kenneth Lebioda, Christopher Halliday, Ewelina Kulikowski, Resverlogix Corporation, Calgary, Canada, Resverlogix Corporation, San Francisco, CA, USA
Abstract embargoed at this time (until March 2)